Travere Therapeutics Analyst Ratings
Wells Fargo Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $27
Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
Scotiabank Initiates Travere Therapeutics at Sector Outperform With $23 Price Target
Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $20 to $41
Travere Therapeutics Analyst Ratings
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $41
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $20
Leerink Partners Reiterates Outperform on Travere Therapeutics, Maintains $20 Price Target
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $22
Travere Therapeutics Is Maintained at Overweight by Barclays
Travere Therapeutics Analyst Ratings
Barclays Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $18
Barclays Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $18
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $17 to $23
Travere Therapeutics Price Target Cut to $19.00/Share From $23.00 by Citigroup
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $18 to $23
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Analyst Ratings